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ABSTRACT 
Objective: Mammary carcinoma is one of the most common and prominent cause of cancer-related death in women worldwide. The role of fatty 
acid synthesis and altered lipid metabolism in cancer progression was well established. Cancer cells undergo enhanced de-novo lipogenesis and liver 
uptake. The magnitudes of bioflavonoids in lipid management against various cancers have been established. In the present study, we evaluated the 
efficacy of a bioflavonoid Naringenin (NGN) to re-establish the lipid metabolic alterations in 7, 12-dimethyl benz (a) anthracene (DMBA)-induced 
mammary carcinoma in Sprague Dawley (SD) rats. 
Methods: DMBA-induced mammary carcinoma was developed using air pouch technique (20 mg in 0.5 ml olive oil) following a 118 d experimental 
protocol. NGN (40, 80 mg/kg b. w.; i. p.) was given for 28 d after promotional stage (90 d) of carcinoma bearing animals. The changes in body weight 
(b. w.), lipids, lipoproteins and lipid metabolising enzymes (LME) level were estimated and correlated with anticancer potentials of NGN. 
Results: The results indicated a dose dependant significant (p<0.05) restorative effect of NGN on body weight of cancer-bearing animals. The 
changes in lipid level in plasma and liver tissue were re-established after treatment. Lipoproteins and LME were also changed in cancer-bearing 
animals with that of NGN treatment significantly (p<0.01). 
Conclusion: NGN potentially reverted the changes in body weight, lipid profile, LME that config. its anticancer potential against mammary 
carcinogenesis. 
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INTRODUCTION 
Breast cancer is a malignant tumour characterised by uncontrolled 
proliferation, invasion and metastasis [1]. Malignant mammary 
carcinoma is one of the most common hormonal cancers among 
women and is the second most prominent cause of cancer-related 
death in females worldwide. According to the American Cancer 
Society, 3.1 million women in US bear invasive breast cancer till Jan 
2014 [2]. Early detection and prevention of some of the cancer 
progression could be possible as up to a certain stage it is a slowly 
progressive disease that takes many years to become invasive. 
Various factors responsible for cancer progression were always 
studied and targeted for the curative approaches. An association has 
reported between lipid and cancer in various epidemiological 
studies [3-5]. It has well established that the neoplastic cells able to 
synthesize lipids like embryonic tissue [6].  
The role of fatty acid synthesis in tumour progression has 
established by many researchers in mammary and prostate cancer 
where increased expression of fatty acid synthase was diagnosed [7, 
8]. Cancer cells showed specific metabolic alterations and enhanced 
synthesis of proteins, nucleic acids and lipids for their rapid 
proliferation and progression [9, 10]. Besides this increased lipid 
consumption and biogenesis by cancer cells supported by a huge 
literature [11, 12]. This represents the necessity of lipid by 
carcinoma cells for various structural functionality like cholesterol-
rich membrane rafts for plasma membrane functions, the 
functionality of membranous organelles like mitochondria and ER, to 
increase membrane lipid saturation for the protection of cancer cells 
from oxidative damage by reducing lipid peroxidation [10, 13, 14].  
The magnitude of bioflavonoids in disease management is far and 
wide. The scientific substantiation consistently revealed an 
association between dietary intake of naturally occurring bioactive 
molecules and cancer biology.  
 
Fig. 1: Structure of NGN 
 
Naringenin (NGN, 5, 7-dihydroxy-2-(4-hydroxyphenyl) chroman-4-
one) is a flavanone bioflavonoid that is abundant in citrus fruits and 
tomatoes [15]. It has been pharmacologically evaluated as a 
potential anticancer agent in various cancers and also is effective on 
MCF-7 breast cancer cell line [16]. Although NGN has been reported 
to have lipolytic potential in various fat induced atherosclerosis 
models, its effect on DMBA-induced cholesterol metabolism 
regulation imbalance and lipid management in cancer-bearing 
experimental animals has not studied extensively. 
In the present study, our group has evaluated the efficacy of NGN on 
modification in levels of lipids (triglycerides (TG), phospholipids 
(PL), total cholesterol (TC), free cholesterol (FC) and free fatty acids 
(FFA)), lipoproteins (low-density lipoprotein cholesterol (LDL-c), 
high-density lipoprotein cholesterol (HDL-c) and very low density 
lipoprotein cholesterol (VLDL-c)) and LME (lecithin cholesterol 
acyltransferase (LCAT), lipoprotein lipase (LL) and total lipases (TL), 
cholesterol ester hydrolase (CEH), cholesterol ester synthase (CES)) 
in DMBA-induced mammary carcinoma animals. 
MATERIALS AND METHODS 
Experimental animals and drug preparations 
Female SD rats (50–55 d old) in each group were used in this study. 
Animals have obtained from the central animal facility, Birla 
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Institute of Technology Mesra, Ranchi Jharkhand, India (Registration 
No. 621/02/ac/CPCSEA). All animals were kept in polyacrylic cages 
and maintained under standard conditions (room temperature 24-
27 ºC and humidity 60-65 % with 12:12 light: dark cycles). The food 
was provided in the form of pellets (Hindustan animals feed, Gujrat, 
India) and water ad-libitum. A week before the beginning of 
experiment acclimatization to the laboratory environment has given 
to the animals. All experiments involving animals complies with the 
ethical standards of animals handling, and IAEC approved the study 
protocol (protocol approval no. BIT/PH/IAEC/24/2013). NGN 
(Sigma-Aldrich, India) was suspended in 1% (w/v) carboxymethyl 
cellulose (CDH (P) Ltd, New Delhi, India). 
Cancer induction and treatment protocol  
Mammary tumours were induced by DMBA using the “air pouch 
technique” with some modifications as required [17, 18]. Briefly, 
about 2–3 ml of sterile air was injected subcutaneously just beneath 
the mammary fat pad region of the second and third mammary 
glands. The air inside was stabilized for 24 h to form a pouch. A 
single dose of 20 mg DMBA in 0.5 ml of olive oil was vortexed to 
obtain a uniform suspension and was injected into the air pouch. 
Four experimental groups of six animals in each group used for the 
study as follows:  
Group I: Control, served with 0.5 ml olive oil in air pouch once at day 1. 
Group II: Induced Control, DMBA (20 mg in 0.5 ml olive oil once at 
day1). 
Group III & IV: NGN treatment groups at 40 mg/kg b.w. and 80 
mg/kg b.w. doses respectively for 28 d. 
All rats were checked by palpation every week to monitor 
tumorigenesis. When a tumour was first palpated, the tumour 
location was recorded. NGN treatment was started after attaining 
the promotional stage of tumorigenesis (90 d) from the time of 
carcinogen administration. Adenocarcinomas were confirmed by 
histological examinations in cancer-bearing animals after 118 d. 
From day 1, the variations in the body weight during the study 
period were recorded for normal, induced and treatment groups at 
regular interval of 7 d till the experiment was finished (day 118). 
Estimation of lipids, lipoproteins and LME 
Lipid was extorted from the tissue by the technique given by Folch et 
al. [19]. Using the Folch aliquots for tissue and plasma samples all 
the lipid components were estimated. TG was estimated by the 
method of Van Handle [20] with small modifications done by Rice et 
al. [21]. PL was estimated according to the method given by Rouser 
et al. [22]. TC was determined according to the method given by 
Parekh and Jung [23]. FC was determined by enzymic scheme given 
by Leffler and Mc Dougald [24]. FFA was estimated by the technique 
given by Horn and Monahan [25]. Plasma lipoproteins were 
fractionated by dual precipitation technique [26]. The addition of 
heparin–magnesium to plasma precipitated VLDL-c, LDL-c and HDL-
c which were left in the supernatant and subsequently, the content 
was measured in the fraction. LL was estimated in plasma and tissue 
samples according to the method is given by Schmidt [27], TL was 
estimated in both plasma and tissue samples according to the 
method of Bier [28], Estimation was done by the method of Kothari 
et al. [29], the activity of LCAT was assayed using the method of [30] 
with modifications from the method of [31]. 
Statistical analysis 
All experimentally collected data were analyzed through one-way 
analysis of variance (ANOVA) followed by Bonferroni’s multiple 
comparison tests with identical sample size using Graph Pad Prism 
(version 5.0). The variation was considered significant with p<0.05. 
All the values were expressed as mean±standard error mean (SEM). 
RESULTS 
Body weight assessment 
Change in b.w. during 118 d studies was recorded weekly and 
represented graphically in fig 2. The control rat revealed a normal 
increase in b.w. with no signs of abnormality. DMBA-induced rats 
showed a normal increase in b.w. in the early proliferation period of 
6 w. A significant (p<0.01) decrease in b.w. was recorded which 
further accelerated after the 11th
 
 week. A significant (p<0.001) 
decrease in b.w. were recorded as compared to control at last. 
Similar variations were recorded in induction phase as that of 
Induced control and in animals treated with NGN (40 mg/kg b.w.). 
These rats showed a significant (p<0.05) decrease in b.w. when 
compared to control Group I animals after 118 d of study protocol 
whereas a increased level of protection (p<0.01) was recorded in 
animals with the higher dose (80 mg/kg b.w.) of NGN as compared 
to control. Body weights of all NGN treated animals were 
significantly (p<0.05) decreased than that of induced control.  
 
Fig. 2: Effect of DMBA and NGN treatment on experimental 
animals 
Each value shows mean±SEM; n=6. where, a-Group II, III, IV 
compared with Group I, b-Group III, IV compared with Group II,***-
p<0.001, **-p<0.0, *-p<0.05; Group I-normal control; Group II-
Induced Control; Group III-DMBA+NGN(40 mg/kg b.w.); Group IV-
DMBA+NGN (80 mg/kg b.w.) 
 
Effect of NGN on lipids and lipoproteins levels in plasma and 
liver of all experimental animals 
The level of TG, PL, TC, FC and FFA in plasma and liver tissue 
samples for all group animals estimated which are depicted in table 
1. Induced group animals illustrate a significant (p<0.001) raise in 
all lipids level in both samples as compared to control group I 
animals. In plasma samples, NGN treated animals at 40 mg/kg b.w. 
(Group III), showed a significant decrease in lipids which are at a 
level of p<0.05 for PL, TC, FC and of p<0.01 for TG and FFA when 
compared with induced control animals. Group IV (80 mg/kg b.w.) 
animals, recorded to have a significant (p<0.001) decline in all lipids 
level as compared to cancer-bearing group II animals. 
In liver samples, a greater protection level of NGN treatment on 
lipids level can be seen. In group III animals a significant decrease at 
a level of p<0.01 was recorded for TG and PL which was at a level of 
p<0.001 for TC, FC and FFA as compared with induced control group 
animals. At higher doses the levels were significantly (p<0.001) 
decreased for all as compared with induced control. In both samples, 
NGN treatment showed a decrease in all lipids near normalcy when 
compared with control animals in a dose dependent manner as 
depicted in table 1. 
The plasma lipoproteins (HDL-c, LDL-c and VLDL-c) profile for all 
experimental group animals was depicted in fig. 3. DMBA-induced 
untreated group II animals recorded to have significantly (p<0.001) 
declined HDL-c and significant (p<0.001) increase in LDL-c and 
VLDL-c levels as compared to Group I control animals. When treated 
with NGN, Group III animals revealed an insignificant (p>0.05) but 
an raise in HDL-c level and a significant (p<0.01) decline in LDL-c 
and VLDL-c lipoproteins level as compared to cancer-bearing 
untreated animals. Whereas, when treated with high dose (80 mg/kg 
Pattanayak et al. 
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b.w.) Group IV animals revealed a significant (p<0.001) decline in 
HDL-c and significant increase in LDL-c and VLDL-c at a level of 
p<0.001 as compared with induced control group II animals. NGN 
treatment decreased LDL-c and VLDL-c plasma level near normalcy 
at a level of p<0.01 and p<0.05 respectively when compared to 
control group animals. 
 









Free fatty acid 
(mg/dl) 
Lipid levels in Plasma samples of experimental animals 
Group I 40.10±1.16 91.88±1.62 123.85±2.16 93.36±1.14 15.16±0.76 
Group II 68.27±1.92a***b 157.06±1.23a** 145.94±1.89a*** 147.93±1.67a*** 36.17±1.70a*** 
Group III 
*** 
59.98±1.12a***b 105.36±1.12a*** ***b 139.67±1.71a*** **b 132.83±1.51ans ***b 25.47±1.11a*** ***b
Group IV 
*** 
45.89±1.39ansb 98.84±1.46a*** *b 135.31±1.88a*** *b 99.75±0.94a** *b 19.88±0.76a*** nsb
Lipid levels in Liver samples of experimental animals 
*** 
Group I 9.01±0.11 8.04±0.09 4.41±0.06 2.24±0.07 6.75±0.18 
Group II 15.99±0.10a 11.67±0.08a*** 9.14±0.04a*** 4.90±0.08a*** 8.48±0.08a*** 
Group III 
*** 
11.20±0.11a***b 9.48±0.06a*** *** b 5.69±0.08a*** *** b 3.81±0.07a*** *** b 7.69±0.09a*** *** b
Group IV 
*** 
9.65±0.11a**b 8.72±0.07a*** *** b 5.05±0.05a*** *** b 2.67±0.07a*** ** b 7.19±0.08a*** ns b*** 
Each value shows mean±SEM; n=6. where, a-Group II, III, IV compared with Group I, b-Group III, IV compared with Group II,***-p<0.001, **-p<0.0, *-
p<0.05, ns
 
-p>0.05; Group I-normal control; Group II-Induced Control; Group III-DMBA+NGN(40 mg/kg b.w.); Group IV-DMBA+NGN (80 mg/kg b.w.). 
 
Fig. 3: Lipoproteins level in all experimental group animals 
Each value shows mean±SEM; n=6. where, a-Group II, III, IV 
compared with Group I, b-Group III, IV compared with Group II,***-
p<0.001, **-p<0.0, *-p<0.05; Group I-normal control; Group II-
Induced Control; Group III-DMBA+NGN(40 mg/kg b.w.); Group IV-
DMBA+NGN (80 mg/kg b.w.). LDL-c: Low-density lipoprotein 
cholesterol, HDL-c: High-density lipoprotein cholesterol, VLDL-c: 
Very low density lipoprotein cholesterol 
 
Effect of NGN treatment on LME of all experimental group animals 
The modification in levels of lipid metabolising enzymes (LME) were 
estimated in plasma (LCAT, LL, TL) and liver tissue (LCAT, LL, TL, 
CEH, CES) samples of all experimental group animals in fig. 4 and fig. 
5 respectively. DMBA-induced mammary carcinoma bearing 
untreated animals bears a significant (p<0.001) decrease in LCAT 
and LL but a significant (p<0.001) increase in TL in plasma as well as 
liver samples and a significant (p<0.001) increase in CEH and CES in 
liver samples as compared to control group I animals. In plasma 
samples, group III animals showed an insignificant (p>0.05) changes 
in all LME as compared to cancer-bearing group II animals. When 
treated with 80 mg/kg b.w., group IV animals showed a significant 
increase in LCAT and LL at a level of p<0.01 and p<0.05 respectively 
and significantly (p<0.01) decrease TL when compared with induced 
control group II animals. But, a significant (p<0.01) change was 
observed in group III animals that increased with dose (Group IV) 
towards normalization when compared with control group I 
animals. In liver samples, NGN treated group III animals showed a 
significant (p<0.05) decrease in LCAT and LL whereas a significant 
(p<0.05) increase in CEH and CES level with having an insignificant 
increase in TL as compared to tumour bearing animals. On high dose 
NGN treatment, LCAT and LL enzyme levels were significantly (p<0.001) 
decreased and TL, CEH and CES levels were significantly (p<0.001) 
increased in group IV animals as compared to induced control group II 
animals. Normalization was recorded on high dose (80 mg/kg b.w.) 
treatment only when compared with control group I animals. 
 
 
Fig. 4: LME level in plasma of all experimental group animals 
 
Each value shows mean±SEM; n=6. where, a-Group II, III, IV compared 
with Group I, b-Group III, IV compared with Group II,***-p<0.001, **-
p<0.0, *-p<0.05; Group I-normal control; Group II-Induced Control; 
Group III-DMBA+NGN(40 mg/kg b.w.); Group IV-DMBA+NGN (80 
mg/kg b.w.). Units: Lecithin Cholesterol-acyl Transferase (LCAT) (mol 
of cholesterol esterified/h/mg protein), Lipoprotein Lipase (LL) (mol 
of free fatty acid liberated/h/mg protein), Total Lipase (TL) (mol of p-
nitrophenol liberated/h/mg protein) 
DISCUSSION 
Preclinical DMBA-induced mammary carcinoma model in SD-rats 
resembles clinically developed ductal carcinoma using various 
histological and biochemical changes. Anatomical changes like b.w. 
can reflect the abnormality and physiological changes. Cancer 
incidences significantly show consequent weight loss after certain 
duration [32]. In carcinogenesis, irregularity of various pathways 
brings activation or overexpression of several genes involved in lipid 
and lipoprotein synthesis [9]. Various studies reported that 
neoplastic cells/tissues can synthesize lipids or reactivate lipid 
synthesis [6, 7]. Mammary carcinoma exhibits increased expression 
of lipid synthesizing enzymes and machinery that may play a role in 
cancer pathogenesis [8]. But the relation behind increased lipid and 
lipoprotein levels and cancer progression are not defined precisely. 
Previous studies reported that lipid and lipoproteins (LDL/VLDL) 
induce phenotypic changes that result in proliferation and migration 
of mammary carcinoma [33-35]. 
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Fig. 5: LME levels in liver tissues of all experimental group 
animals 
Each value shows mean±SEM; n=6. where, a-Group II, III, IV 
compared with Group I, b-Group III, IV compared with Group II,***-
p<0.001, **p<0.0, *-p<0.05; Group I-normal control; Group II-
Induced Control; Group III-DMBA+NGN(40 mg/kg b.w.); Group IV-
DMBA+NGN (80 mg/kg b.w.). Units: Lecithin Cholesterol-acyl 
Transferase (LCAT) (mol of cholesterol esterified/h/mg protein), 
Lipoprotein Lipase (LL) (mol of free fatty acid liberated/h/mg 
protein), Total Lipase (TL) (mol of p-nitrophenol liberated/h/mg 
protein), Cholesterol Ester Hydrolase (CEH) (mol of cholesterol 
liberated/h/mg protein), Cholesterol Ester Synthetase (CES) (mol of 
cholesterol esterified/h/mg protein). 
 
In our study, increased proliferation and progression of 
carcinogenesis may be correlated with increased total cholesterol 
and triglycerides. Cholesterol and phospholipid content are 
responsible for the fluidity of lipid membrane. Carcinoma increases 
level of cholesterol and phospholipids that may contribute to the 
further progression of cancer [36]. The liver is the major organ 
involved in lipid metabolism and distribution. The alteration in the 
level of lipids, lipoproteins in plasma as well as liver during 
carcinogenesis and tumour progression has been observed 
previously [37]. The changes that occur during cancer progression in 
liver mediated metabolism and lipoprotein-mediated transportation 
brings the plasma lipid level change. The apolipoprotein-B mediated 
modulation of low-density lipoprotein receptors results in LDL-c 
rush into the plasma [22]. The increased synthesis of LDL-c and 
VLDL-c ultimately elevate total cholesterol and triglycerides 
respectively in mammary carcinoma bearing animals. The reduced 
level of HDL-c is mainly compensated by LDL-c and vice versa hence 
in cancer-bearing animals the increased level of LDL-c and VLDL-c 
can be justified [25]. The changes in lipid metabolising enzymes can 
be correlated with progressive carcinogenesis. LCAT and LL control 
the clearing of free cholesterol and triglycerides from the plasma by 
etherification and cleavage respectively [22].  
Hence increased the level of triglycerides, total cholesterol and free 
cholesterol in untreated cancer bearing animals was recorded due to 
reduced activities of these fat-splitting enzymes. Increased 
lipogenesis in cancer-bearing animals was mediated by large 
production of lipid peroxides. Hyperlipidemia could reflect the 
increased activity of TL during progressive carcinogenesis [18]. The 
elevation in total body fat was associated with increased total lipase 
activity in mammary carcinoma bearing subjects when compared 
with normal one was reported [38]. Low level of plasma cholesterol 
was maintained by LCAT by increasing incursion of ester cholesterol 
into the cells. In mammary carcinoma bearing animals, low LCAT 
levels result in increased plasma cholesterol contents. Also, LCAT 
mediates formation of HDL-c which is reduced due to reduced 
activity of the enzyme. Lipoprotein activity was inhibited by HDL by 
competing with the enzyme substrate in cancer-bearing animals. 
This inhibition of LCAT makes avail more lipids to the cell 
contributing further proliferation of carcinoma cells. CEH and CES 
enzymes maintain cholesterol balance inside the cell. The 
disproportion in the level of cholesterol may result due to the 
hyperlipidemia conditions. The subsistence of a causal association 
between a elevated lipid content and superior cancer risk has 
reported as one of the mechanisms of cellular abnormality by 
interaction with various signalling pathways that leads to 
transformed gene expression, effects on liberated oestrogenic 
concentration (in case of mammary carcinoma) and anatomical & 
physiological alterations in cell membranes resulting in modification 
in hormone and growth factor receptors [18]. Hence, NGN 
potentially quashes the alterations in lipid metabolism and plasma 
and tissue levels of lipids in DMBA-induced mammary carcinoma 
bearing animals when compared with normal levels of control group 
animals. 
CONCLUSION 
From the above results, we can conclude that NGN treatment to 
DMBA-induced cancer-bearing female SD-rats in their promotional 
stage of multistage carcinogenesis brings restorative changes in the 
altered lipid, lipoproteins and LME levels. It also normalizes the 
decrease in the body weight (like untreated animals) when 
compared with normally growing control group animals. Herbal 
compounds could exhibit multiple mechanisms behind their 
anticancer activity. Although the underlying mechanisms were not 
precisely known, but from this part of the study, we can conclude that 
re-establishment of body weight, lipid metabolism alterations and 
underlying enzymic changes, could be one of the prospective for the 
anticancer potential of NGN against mammary carcinoma condition.  
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